Stocks Health care XBIO
NASDAQ · Health careXenetic Biosciences, Inc. (XBIO)
Xenetic Biosciences, Inc. brought in $3.3M of revenue over the twelve months to June 30, 2026, up 33.3% from a year earlier. It posted a net loss of $2.5M. At June 30, 2026 it held $6.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Xenetic Biosciences, Inc. does
Xenetic Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker XBIO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $3M | -$2.7M | -$1.58 | n/a |
| 2024 | $2.5M | -$4M | -$2.57 | n/a |
| 2023 | $2.5M | -$4.1M | -$2.71 | n/a |
| 2022 | $1.7M | -$6.6M | -$4.61 | n/a |
| 2021 | $1.2M | -$5.6M | -$5.51 | n/a |
| 2020 | $436.9K | -$10.9M | -$17.04 | n/a |
Full financial statements: income, balance sheet and cash flow
Where XBIO ranks in Health care
Latest SEC filings
What Xenetic Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 23, 2026
- September 18, 2026Passive stake (5% or more) SCHEDULE 13G
- September 16, 2026
- August 7, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 12% to $660.6K versus the same quarter last year; diluted EPS -$0.41 versus -$0.45.
- May 29, 2026Passive stake (5% or more) SCHEDULE 13G
- May 14, 2026Passive stake changed SCHEDULE 13G/A
- May 13, 2026
- May 12, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 36% to $806.9K versus the same quarter last year; diluted EPS -$0.20 versus -$0.59.
- April 24, 2026Annual report (amended) 10-K/A · period to December 31, 2025Revenue rose 19% to $3M versus the prior year; diluted EPS -$1.58 versus -$2.57.
Who owns XBIO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Renaissance Technologies LLC13G, passive with 1 related filers | 6% | May 14, 2026 |
Largest institutional holders
Insiders
Questions about XBIO
What does Xenetic Biosciences, Inc. do?
Xenetic Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker XBIO.
Is Xenetic Biosciences, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $2.5M on revenue of $3.3M.
How much revenue does Xenetic Biosciences, Inc. make?
Over the twelve months to June 30, 2026 Xenetic Biosciences, Inc. reported revenue of $3.3M. That is 33.3% more than a year earlier.
When did Xenetic Biosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 23, 2026.
Similar companies
Compare XBIO with
Follow XBIO
Get an email when Xenetic Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow XBIO: get an email when it filesWhere the numbers come from
Financial figures are the values Xenetic Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.